Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Annals of Hematology
Erschienen in: Annals of Hematology 6/2012

01.06.2012 | Original Article

SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma

verfasst von: Giovanni Barosi, Giampaolo Merlini, Atto Billio, Mario Boccadoro, Paolo Corradini, Monia Marchetti, Massimo Massaia, Patrizia Tosi, Antonio Palumbo, Michele Cavo, Sante Tura

Erschienen in: Annals of Hematology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

In this project, we produced drug-specific recommendations targeting the use of new agents for multiple myeloma (MM). We used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system which separates the judgments on quality of evidence from the judgment about strength of recommendations. We recommended thalidomide and bortezomib in MM patients candidates to autologous stem cell transplantation (ASCT) (weak positive). We did not recommend novel agents as maintenance therapy after ASCT (weak negative). In patients not candidate to ASCT, thalidomide or bortezomib (strong positive) associated with melphalan and prednisone were recommended. In these patients, no specific course of action could be recommended as for maintenance therapy. In patients who are refractory or relapsing after first-line therapy, we recommended bortezomib and pegylated liposomal doxorubicin, or lenalidomide and dexamethasone combinations (weak positive).
Literatur
1.
Brenner H, Gondos A, Pulte D (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111:2521–2526PubMedCrossRef
2.
Kastritis E, Zervas K, Symeonidis A et al (2009) Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 23:1152–1157PubMedCrossRef
3.
Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520PubMedCrossRef
4.
Barosi G, Boccadoro M, Cavo M et al (2004) Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 89:717–741PubMed
5.
Brouwers MC, Kho ME, Browman GP et al (2010) AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med 51:421–424PubMedCrossRef
6.
Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490–1498PubMedCrossRef
7.
Ferguson JH (1996) The NIH Consensus Development Program. The evolution of guidelines. Int J Technol Assess Health Care 12:460–474PubMed
8.
William PL, Webb C (1994) The Delphi technique: a methodological discussion. J Adv Nurs 19:180–186CrossRef
9.
Delbecq AL, van de Ven AH, Gustafson DH (1975) Group Techniques for Program Planning: a guide to nominal group and Delphi processes. Scott Foresman and Co, Glenview
10.
Hicks L, Haynes A, Reece D et al (2008) A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 34:442–452PubMedCrossRef
11.
Lokhorst HM, van der Holt B, Zweegman S et al (2010) A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115:1113–1120PubMedCrossRef
12.
Harousseau JL, Attal M, Avet-Loiseau H et al (2010) Bortezomib–dexamethasone is superior to vincristine–doxorubicin–dexamethasone as induction prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: results of the IFM2005-01 phase 3 trial. J Clin Oncol 28:4621–4629PubMedCrossRef
13.
Sonneveld P, Schmidt-Wolf I, van der Holt B et al (2008) HOVON-65/GMMG-HD4 Randomized Phase III Trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood 112:653, suppl; abstr 307
14.
Rajkumar SV, Jacobus S, Callander NS et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29–37PubMedCrossRef
15.
Cavo M, Tacchetti P, Patriarca F et al (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075–2085PubMedCrossRef
16.
Cavo M, Pantani L, Patriarca L et al (2011) Superior complete response rate (CR) and progression-free survival (PFS) with bortezomib–thalidomide–dexamethasone (VTS) versus thalidomide–dexamnethasopne (TD) as consolidation therapy after autologous stem-cell transplantation (ASCT) in multiple mueloma (MM). Blood 118:816, suppl; abstr 1871CrossRef
17.
Harousseau J-L, Avet-Loiseau H, Facon T et al (2009) Bortezomib plus dexamethasone (VD) versus reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) as induction treatment prior to autologous stem-cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood 114:150, suppl; abstr 354
18.
Rosiñol L, Cibeira MT, Mateos MV et al (2010) A Phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib. Blood 116:139, suppl; abstr 307CrossRef
19.
Attal M, Harousseau JL, Leyvraz S et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289–3294PubMedCrossRef
20.
Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021–1030PubMedCrossRef
21.
Spencer A, Prince HM, Roberts AW et al (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27:1788–1793PubMedCrossRef
22.
Stewart AK, Trudel S, Bahlis N et al (2010) A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): The NCIC CTG MY.10 trial. Blood 116:23, suppl; abstr 39CrossRef
23.
Morgan GJ, Gregory WM, Davies FE et al (2012) The role of maintenance therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119:7–15PubMedCrossRef
24.
Nooka AK, Begera M, Boise LH et al (2011) Thaldomide as maintenance therapy in multiple myeloma (MM) improves progression free survival (PFS) and overall survival (OS): a meta-analysis. Blood 118:807, suppl; abstr 1855
25.
Attal M, Lauwers VC, Marit G et al (2010) Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02. Blood 116:141, suppl; abstr 310
26.
McCarthy PL, Owzar K, Anderson KC et al (2010) Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104. Blood 116:21, suppl; abstr 37
27.
Rosinol L, Cibeira MT, Masteros MV et al (2011) A phase III PETHEMA/GEM randomized trial of postransplant (ASCT) maintenance in multiple myeloma: superiority of bortezomib/thalidomide compared with thaluidomide and alpha-2b interferon. Blood 118:1694, suppl; abstr 3962
28.
Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825–831PubMedCrossRef
29.
Palumbo A, Bringhen S, Liberati AM et al (2008) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized trial. Blood 112:3107–3114PubMedCrossRef
30.
Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370:1209–1218PubMedCrossRef
31.
Hulin C, Facon T, Rodon P et al (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27:3664–3670PubMedCrossRef
32.
Waage A, Gimsing P, Fayers P et al (2010) Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116:1405–1412PubMedCrossRef
33.
Beksac M, Haznedar R, Firatli-Tuglular T et al (2011) Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 86:16–22PubMedCrossRef
34.
Wijermans P, Schaafsma M, Termorshuizen F et al (2010) Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 28:3160–3166PubMedCrossRef
35.
Fayers PM, Palumbo A, Hulin C et al (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118:1239–1247PubMedCrossRef
36.
Rajkumar SV, Blood E, Vesole D et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–436PubMedCrossRef
37.
Rajkumar SV, Rosinol L, Hussein M et al (2008) Multicenter, randomized, double blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26:2171–2177PubMedCrossRef
38.
Ludwig H, Hajek R, Tothova E et al (2009) Thalidomide–dexamethasone compared to melphalan–prednisolone in elderly patients with multiple myeloma. Blood 13:3435–3442CrossRef
39.
Morgan GJ, Davies FE, Gregory WM et al (2011) Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118:1231–1238PubMedCrossRef
40.
San-Miguel J, Schlag R, Khuageva N et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917PubMedCrossRef
41.
Mateos MV, Richardson PG, Schlag R et al (2010) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28:2259–2266PubMedCrossRef
42.
San-Miguel J, Schlag R, Khuageva NK et al (2011) Continued overall survival benefit after 5 years’ follow-up with bortezomib–melphalan–prednisone (VMP) versus melphalan–prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 VISTA trial. Blood 118:221, suppl; abstr 476
43.
Palumbo A, Delforge M, Catalano J et al (2010) A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥ 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens. Blood 116:273, suppl; abstr 622CrossRef
44.
Zonder JA, Crowley J, Hussein MA et al (2010) Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 116:5838–5841PubMedCrossRef
45.
Mateos MV, Oriol A, Martínez-López J et al (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11:934–941PubMedCrossRef
46.
Palumbo A, Bringhen S, Rossi D et al (2010) Bortezomib–melphalan–prednisone–thalidomide followed by maintenance with bortezomib–thalidomide compared with bortezomib–melphalan–prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28:5101–5109PubMedCrossRef
47.
Bringhen S, Larocca A, Rossi D et al (2010) Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116:4745–4753PubMedCrossRef
48.
Nievizky R, Flinn IW, Rifkin R et al (2011) Efficacy and safety of three bortezomib–based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. Blood 118:222, suppl; abstr 478
49.
Palumbo A, Adam Z, Kropff M et al (2011) A phase 3 study evaluating the efficacy and safety of lenalidomide (Len) combined with melphalan and prednisone followed by continuous lenalidomide maintenance (MPR-R) in patients (Pts) ≥ 65 years (Yrs) with newly diagnosed multiple myeloma (NDMM): updated results for Pts aged 65–75 < Yrs enrolled in MM-015. Blood 118:220, suppl; abstr 475CrossRef
50.
Mateos MV, Oriol A, Tereul A-I et al (2011) Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patients included in the GEM2005MAS65 Spanish randomized trial. Blood 118:222, suppl; abstr 477CrossRef
51.
Ludwig H, Adam Z, Tóthová E et al (2010) Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 95:1548–1554PubMedCrossRef
52.
Richardson PG, Sonneveld P, Schuster MW et al (2005) Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498PubMedCrossRef
53.
Richardson PG, Sonneveld P, Schuster M et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110:3557–3560PubMedCrossRef
54.
Lee SJ, Richardson PG, Sonneveld P et al (2008) Bortezomib is associated with better health-related quality of life than high dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 143:511–519PubMed
55.
Orlowski RZ, Nagler A, Sonneveld P et al (2007) Randomized phase III study of pegylated liposomal Doxorubicin plus Bortezomib compared with Bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 28:3892–3901CrossRef
56.
Sonnevel P, Hajek R, Nagler A et al (2008) Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 112:1529–1537CrossRef
57.
Weber D, Chen C, Niesvizky R et al (2007) Lenalidomide plus Dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142PubMedCrossRef
58.
Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132PubMedCrossRef
59.
Dimopoulos MA, Chen C, Spencer A et al (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23:2147–2152PubMedCrossRef
60.
Chen C, Reece DE, Siegel D et al (2009) Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 146:164–170PubMedCrossRef
61.
Dimopoulos MA, Hussein M, Swern AS et al (2011) Long-term outcomes and safety of continuous lenalidomide plus dexamethasone (Len + Dex) treatment in patients (Pts) with relapsed or refractory multiple myeloma (RRMM). Blood 118:1263, suppl; abstr 2929CrossRef
62.
63.
Schunemann HJ, Jaeschke R, Cook DJ et al (2006) An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 174:605–614PubMedCrossRef
64.
Kumar SK, Mikhael JR, Buadi FK et al (2009) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 84:1095–1110PubMedCrossRef
65.
NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma, version 1.2011
66.
Bird JM, Owen RG, D’Sa S et al (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154:32–75PubMedCrossRef
67.
Palumbo A, Sezer O, Kyle R et al (2009) IMWG International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23:1716–1730PubMedCrossRef
68.
Ghobrial IM, Stewart AK (2009) ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma? Hematology Am Soc Hematol Educ Program 587–589
69.
De Palma R, Liberati A, Ciccone G et al (2008) Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group. J Clin Oncol 26:1033–1039PubMedCrossRef
Metadaten
Titel
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma
verfasst von
Giovanni Barosi
Giampaolo Merlini
Atto Billio
Mario Boccadoro
Paolo Corradini
Monia Marchetti
Massimo Massaia
Patrizia Tosi
Antonio Palumbo
Michele Cavo
Sante Tura
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 6/2012
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1445-y

Weitere Artikel der Ausgabe 6/2012

Annals of Hematology 6/2012 Zur Ausgabe

Letter to the Editor

Targeted (not global) iron supplementation/fortification is the issue!

Letter to the Editor

Anemia and global iron fortification and supplementation

Letter to the Editor

Successful transfusion care for a patient with the Rhesus -D- phenotype and antibodies against Rh17 and two additional alloantibodies

Original Article

A useful relationship between the presence of extramedullary erythropoeisis and the level of the soluble form of the transferrin receptor in a large cohort of adult patients with thalassemia intermedia: a prospective study

Original Article

Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment

Original Article

A novel ELISA for diagnosis of Glanzmann’s thrombasthenia and the heterozygote carriers

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise